查詢結果分析
相關文獻
- 高血壓與慢性腎臟性疾病
- AROTINOLOL治療原發性高血壓的臨床研究
- 運動對高血壓的影響
- Unexpected Pheochromocytoma--A Case Report of Anesthesia in a Uremic Patient
- Relationship between Microalbuminuria, Left Ventricular Mass and Function in Essential Hypertension
- The Effect of Sphenopalatine Postganglionic Neurotomy on the Alteration of Local Cerebral Blood Flow of Normotensive and Hypertensive Rats in Acute Cold Stress
- 衛生教育對於榮民之家高血壓老人自我照顧行為與血壓控制之影響
- 長期阻斷內生性一氧化氮對血壓的影響:正常鼠與高血壓鼠間的比較
- Comparison of Clinical Efficacy and Adverse Effects between Extended-release Felodipine and Slow-release Diltiazem in Patients with Isolated Systolic Hypertension
- 同時多發性高血壓腦出血--病例報告
頁籤選單縮合
題 名 | 高血壓與慢性腎臟性疾病=Hypertension and Chronic Kidney Disease |
---|---|
作 者 | 蔡佩芬; 許育瑋; | 書刊名 | 藥學雜誌 |
卷 期 | 26:1=102 2010.03[民99.03] |
頁 次 | 頁126-131 |
分類號 | 418.221 |
關鍵詞 | 慢性腎臟性疾病; 高血壓; 腎素-血管張力素-醛類脂醇系統; Chronic kidney disease; Hypertension; Renin-angiotensin-aldosterone system; |
語 文 | 中文(Chinese) |
中文摘要 | 根據美國腎臟病資料登錄系統的統計資料,慢性腎臟性疾病及末期腎臟疾病在全世界幾乎所有的國家皆有持續增加的趨勢。血壓過高是慢性腎臟性疾病中一個很重要的致病因素,它會加速腎臟功能的惡化,以及增加病人發生心血管疾病的危險性;而腎臟性疾病的存在則是頑固性高血壓常見且低估的已存在醫療因素,其兩者關係密不可分。因此,早期檢查和高血壓治療的介入在防治慢性腎臟性疾病的發生及惡化是很重要的。根據美國國家腎臟基金會臨床指導準則建議,高血壓合併慢性腎臟性疾病的病人血壓值應控制在 130/80 mmHg以下。治療上有兩個主要的目標: (1)降低血壓; (2)以血管張力素轉換酶抑制劑或血管張力素受器阻斷劑來阻斷腎素 -血管張力素 -醛類脂醇系統。治療高血壓合併慢性腎臟性疾病,最重要的是降低血壓,對於大多數病患而言,要達到目標血壓通常更需要非藥物與藥物的治療。 |
英文摘要 | According to the United States Renal Data System, the frequency of chronic kidney disease continues to increase worldwide, and so does the prevalence of End-Stage Renal Disease. High blood pressure is a key pathogenic factor that contributes to the deterioration of kidney function and increase cardiovascular risk. The presence of kidney disease is a common and underappreciated pre-existing medical cause of resistant hypertension. Hypertension and chronic kidney disease are closely linked and inseparable. As a result, it is very important to have a check up early and also the treatment of hypertension has become the most important intervention in reduction of CKD. The National Kidney Foundation Clinical Practice Guidelines recommend that target blood pressure should be <130/80 mmHg for all CKD patients. There are 2 main treatment goals for those with hypertensive CKD: (1) lower the blood pressure and (2) block the renin-angiotensin-aldosterone system with an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin-receptor blocker. The most important aspect of management of hypertensive CKD is to decrease blood pressure. In most cases, achieving this goal requires both non-pharmacologic and pharmacologic intervention. |
本系統中英文摘要資訊取自各篇刊載內容。